[Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Aggressive variants of prostate cancer (AVPC) are a diverse group of tumors with unique characteristics. Research into their subtypes and new treatments, including chemotherapy and immunotherapy, is crucial for improving patient outcomes.
Area Of Science
- Oncology
- Cancer Biology
- Genetics
Context
- Aggressive variants of prostate cancer (AVPC) present unique clinical challenges, including PSA-negative progression and distinct metastatic patterns.
- AVPC are a heterogeneous group, classified into four subgroups: neuroendocrine prostate cancer (NEPC), amphicrine, androgen receptor-low, and double-negative prostate cancer.
- The transformation to AVPC involves critical tumor suppressor gene inactivation (RB1, PTEN, TP53) and epigenetic alterations driving stem cell-like properties.
Purpose
- To provide an overview of the heterogeneity and key molecular drivers of aggressive variants of prostate cancer (AVPC).
- To outline current treatment strategies and emerging therapeutic approaches for AVPC.
- To emphasize the need for clinical trial participation to advance evidence-based treatment for AVPC.
Summary
- AVPC are characterized by androgen-independent growth, PSA-negative progression, and specific metastatic patterns.
- Subtyping AVPC (NEPC, amphicrine, AR-low, double-negative) is challenging but crucial for treatment selection.
- Key molecular events include inactivation of RB1, PTEN, and TP53, alongside epigenetic changes promoting stemness.
Impact
- Understanding AVPC heterogeneity aids in developing targeted therapies.
- Current treatments involve platinum-based chemotherapy, with novel approaches including PARP inhibitors, checkpoint inhibitors, and immunomodulators.
- Promising results with T-cell engagers, especially in NEPC, highlight the potential of immunotherapy.
- Clinical trial enrollment is vital to generate robust evidence and improve treatment paradigms for aggressive prostate cancer.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...